icad — Merger or Acquisition (December 2010)
30 slides from icad's merger presentation, Dec 17, 2010
Slide 1: iCAD Acquisition of Xoft
iCAD Acquisition of Xoft December 17, 2010 11:00 AM EST
Slide 2: Safe Harbor Statement
Safe Harbor Statement 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties. Such forward-looking statements involve a number of known and unknown risks, uncertainties and ot
Slide 3: 2011 - A Transformative Year for iCAD
2011- A Transformative Year for iCAD From To A leader in image analysis and workflow for the detection of the most prevalent cancers A broader portfolio of oncology solutions that provide targeted analysis, therapy and monitoring throughout the cancer care cycle Strategic re-alignment of the company
Slide 4: The Future of Cancer Care
The Future of Cancer Care Collaborative, multi-disciplinary approach Greater focus on early detection Highly personalized treatments that are less invasive and minimize impact on patient quality of life Focus on increasing access to care and decreasing cost Accelerated care cycle that minimizes the
Slide 5: iCAD/Xoft Positioning
iCAD/Xoft Positioning iCAD/Xoft will be a medical technology company that accelerates the adoption of new standards of care in oncology. Our combined innovative solutions will empower clinicians to improve patient outcomes through collaborative delivery of more targeted cancer detection, diagnosis,
Slide 6: Strategic Rationale for Xoft Acquisition
Strategic Rationale for Xoft Acquisition An oncology-based pathway is highly attractive to support iCAD's future growth Strong fit with our existing business Favorable market dynamics in key sub-segments Strong ties to women's health and imaging Supports a multi-disciplinary/collaborative approach t
Slide 7: Strategic Rationale for Xoft Acquisition - continued
Strategic Rationale for Xoft Acquisition - continued Both companies offer platform technologies that can accelerate changes in standards of care and can be leveraged to other cancer types Xoft extends the reach of iCAD's technology to new customer segments and dramatically increases the size of iCAD
Slide 8: Expanding iCAD's Oncology Strategy
Expanding iCAD's Oncology Strategy A Targeted Approach for Detection, Diagnosis and Therapy Monitoring Treatment Diagnosis Detection Cancer Care Cycle Quantitative analysis (SpectraLook and VividLook) Breast biopsy guidance Multi-parametric maps MR Prostate biopsy* US/MR fusion prostate* biopsy Digi
Slide 9: Xoft Overview
ee y 2 x Xoft Overview j 7 @@ cies
Slide 10: Xoft's Current Position in the Radiation Oncology Market
Xoft's Current Position in the Radiation Oncology Market Disruptive and differentiated proprietary platform treating a wide array of cancers Miniaturized non-radioactive source dramatically lowers costs while delivering therapy comparable to existing treatment modalities 2008: Launched FDA-cleared b
Slide 11: The Axxent System Today
The Axxent System Today Breast Other Cancers 11 Miniaturized X-ray Source Controller
Slide 12: Core Xoft Technology: Non-radioactive X-ray Source
Core Xoft Technology: Non-radioactive X-ray Source Miniaturized X-ray tube technology Fully disposable device Recurring revenue stream Non-radioactive treatment system Rapid treatment times but low energy Miniaturized X-ray Source: Detailed View Miniaturized X-ray Source Cooling connections HV conne
Slide 13: Why eBx?
Why eBx(tm)? No shielded vault required Platform technology - large existing market opportunity Non-radioisotope source Enables IORT Minimizes dose to healthy tissue Medical staff can remain in the room with the patient, as determined by the facility Radiation Safety Officer Portability increases ma
Slide 14: Xoft: A Platform Technology in Cancer Care
Xoft: A Platform Technology in Cancer Care eBx treats a wide array of cancers with unique advantages in several indications (1) American Cancer Society; Cancer Facts and Figures 2010. (2) American Cancer Society; Cancer Facts and Figures 2010 NIH, SEER Incidence Data; NCCN Data; 4 American Cancer So
Slide 15: Breast Market/IORT Intraoperative Radiation Therapy
Breast Market/IORT Intraoperative Radiation Therapy
Slide 16: The Clinical Problem in the United States
The Clinical Problem in the United States In the U.S. there are approximately 261,000 new breast cancer cases per year and 168,400 are considered early stage breast cancer and eligible for APBI/IORT Most of these patients should receive radiation treatment following lumpectomy based on published pro
Slide 17: Radiation Therapy Has Changed: Shorter Treatment Times
Radiation Therapy Has Changed: Shorter Treatment Times 6 - 7 weeks of treatment WBRT (Whole Breast Radiation Therapy) 5 days twice a day APBI (Accelerated Partial Breast Irradiation) 12 min ave. during surgery IORT (Intraoperative Radiation Therapy) 17
Slide 18: Clinical Advantages of eBx IORT
Clinical Advantages of eBx IORT RT Dose Optimized 50 kv dose is precisely delivered to the area at greatest risk of tumor recurrence (or persistence) Customized internal shielding allows the physician to protect dose-limiting normal tissues A single dose of eBx intraoperatively can replace 6-7 weeks
Slide 19: IORT Combining Surgery and Treatment In One Day
September 3rd, 2008 AM 7:45---Patient enters hospital 8:45--- Patient set up in OR 9:00---Sentinal node biopsy removed and sent to pathology 9:20---Lumpectomy performed 9:50---Balloon placed and radiation begins 10:02 Radiation complete and oncoplastic work commences 10:45 Surgery completed 11:45 Pa
Slide 20: Physician testimonials on IORT
"I believe that giving a single fraction of radiation at the time of surgery will be advantageous because it will allow all the radiation to be delivered before any remaining tumor cells have a chance to grow. In addition, due to the dose distribution of the electronic brachytherapy source, it will
Slide 21: Gynecology & Dermatology Markets
Gynecology & Dermatology Markets
Slide 22: Market Size for Gynecology
Market Size for Gynecology Estimated 634,800 WW new cases per year of cervical and endometrial cancer* 80% in developing countries due to lack of screening Approximately 42,000 cases per year in the U.S. Approximately 30,000 patients per year in the U.S. are candidates for eBx Growth Drivers for eBx
Slide 23: Dermatology Market
Dermatology Market The Skin Market At approximately 3.5 million cases per year, non-melanoma skin cancer has the highest incidence rate of any cancer in the U.S. Electronic brachytherapy is a treatment alternative for more than 46% of all NMSC Currently Dermatologist treat approximately 80% of all N
Slide 24: Clinical Studies & Reimbursement
Clinical Studies & Reimbursement
Slide 25: Targit-A Trial Summary
Targit-A Trial Summary A Landmark Study for IORT and a Catalyst for Reimbursement Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomized, non-inferiority phase 3 trial (Vaidya et al) The Lancet online, June
Slide 26: Reimbursement Update
Reimbursement Update Anticipated Timeline for CPT 1 Q3 2010 - ASTRO Applied for CPT Level 1 - Single fraction IORT 2012 2011 2010 February - RUC review of CPT Level 1 for IORT July 2011 Targeted CPT Level 1 approval Q4 - Apply for Multi- fraction CPT Level 1 Q4 2011 CPT Level 1 rate is determined Ja
Slide 27: International Growth Opportunities
International Growth Opportunities
Slide 28: International Growth Opportunities
International Growth Opportunities Europe IORT trials have been underway in Europe for 10 years IORT gaining traction in Europe (notably Italy and Germany) with release of TARGIT trial results Breast IORT has a 10 year history of use with several thousand patients treated Rest of World Strong intern
Slide 29: International Distribution
International Distribution Over 100 distributors worldwide have expressed interest in distributing Xoft worldwide In discussions with 5-6 top players in key regions Current/pending distribution agreements cover: Mexico South Korea Northern/Southern Europe Targeted countries/regions include: China In
Slide 30: iCAD/Xoft: A Compelling Future
iCAD/Xoft: A Compelling Future A powerful combination of disruptive platform technologies that enable early detection and early intervention in the oncology care cycle Strategically positions iCAD at the leading edge of targeted detection and therapy Recent events relative to clinical studies and re